anonymous
Guest
anonymous
Guest
Not yet, but they will soon be.....make it easy to write, give it a fair price, take the time and get it covered on formulary.....let Amgen work out the bugs for us.....recipe for a big roll out in Primary Care where the migraine issues first show up. Sounds logical to me. Two sales forces at Lilly selling as a team vs. Amgen and Novartis fighting over who is the better company (good luck with that). Amgen/Novartis you might be first to market.....but first to market usually means finishing 2nd or 3rd as a commercial success in the years to come. Time to move over and let us show you how to roll out and successfully launch a migraine med. You only get one chance to make a first impression! Time will tell but I'm putting my money on Lilly!
time will tell but Lilly launches poorly. They have no presence in Neurology and relationships are tough to form in neurology. Access is poor. Primary care are not writing this--except a handful here and there. Very slow uptake in primary care. The jobs in PCP for this Lilly CGRP will be awful. Chasing your tail and scripts.